837 related articles for article (PubMed ID: 18451260)
1. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism.
Holland WL; Summers SA
Endocr Rev; 2008 Jun; 29(4):381-402. PubMed ID: 18451260
[TBL] [Abstract][Full Text] [Related]
2. Ceramides - Lipotoxic Inducers of Metabolic Disorders.
Chaurasia B; Summers SA
Trends Endocrinol Metab; 2015 Oct; 26(10):538-550. PubMed ID: 26412155
[TBL] [Abstract][Full Text] [Related]
3. Sphingolipids: players in the pathology of metabolic disease.
Cowart LA
Trends Endocrinol Metab; 2009 Jan; 20(1):34-42. PubMed ID: 19008117
[TBL] [Abstract][Full Text] [Related]
4. Sphingolipids and Lipoproteins in Health and Metabolic Disorders.
Iqbal J; Walsh MT; Hammad SM; Hussain MM
Trends Endocrinol Metab; 2017 Jul; 28(7):506-518. PubMed ID: 28462811
[TBL] [Abstract][Full Text] [Related]
5. Sphingolipids: agents provocateurs in the pathogenesis of insulin resistance.
Lipina C; Hundal HS
Diabetologia; 2011 Jul; 54(7):1596-607. PubMed ID: 21468641
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance.
Holland WL; Brozinick JT; Wang LP; Hawkins ED; Sargent KM; Liu Y; Narra K; Hoehn KL; Knotts TA; Siesky A; Nelson DH; Karathanasis SK; Fontenot GK; Birnbaum MJ; Summers SA
Cell Metab; 2007 Mar; 5(3):167-79. PubMed ID: 17339025
[TBL] [Abstract][Full Text] [Related]
7. Sphingolipids and insulin resistance: the five Ws.
Summers SA
Curr Opin Lipidol; 2010 Apr; 21(2):128-35. PubMed ID: 20216312
[TBL] [Abstract][Full Text] [Related]
8. A ceramide-centric view of insulin resistance.
Chavez JA; Summers SA
Cell Metab; 2012 May; 15(5):585-94. PubMed ID: 22560211
[TBL] [Abstract][Full Text] [Related]
9. Sphingolipids in obesity and related complications.
Boini KM; Xia M; Koka S; Gehr TW; Li PL
Front Biosci (Landmark Ed); 2017 Jan; 22(1):96-116. PubMed ID: 27814604
[TBL] [Abstract][Full Text] [Related]
10. Sphingolipids in metabolic disease: The good, the bad, and the unknown.
Green CD; Maceyka M; Cowart LA; Spiegel S
Cell Metab; 2021 Jul; 33(7):1293-1306. PubMed ID: 34233172
[TBL] [Abstract][Full Text] [Related]
11. Sphingolipids in High Fat Diet and Obesity-Related Diseases.
Choi S; Snider AJ
Mediators Inflamm; 2015; 2015():520618. PubMed ID: 26648664
[TBL] [Abstract][Full Text] [Related]
12. Sphingolipid synthetic pathways are major regulators of lipid homeostasis.
Worgall TS
Adv Exp Med Biol; 2011; 721():139-48. PubMed ID: 21910087
[TBL] [Abstract][Full Text] [Related]
13. Sphingolipids: major regulators of lipid metabolism.
Worgall TS
Curr Opin Clin Nutr Metab Care; 2007 Mar; 10(2):149-55. PubMed ID: 17285002
[TBL] [Abstract][Full Text] [Related]
14. CerS6-Derived Sphingolipids Interact with Mff and Promote Mitochondrial Fragmentation in Obesity.
Hammerschmidt P; Ostkotte D; Nolte H; Gerl MJ; Jais A; Brunner HL; Sprenger HG; Awazawa M; Nicholls HT; Turpin-Nolan SM; Langer T; Krüger M; Brügger B; Brüning JC
Cell; 2019 May; 177(6):1536-1552.e23. PubMed ID: 31150623
[TBL] [Abstract][Full Text] [Related]
15. Sphingolipid metabolism and analysis in metabolic disease.
Brice SE; Cowart LA
Adv Exp Med Biol; 2011; 721():1-17. PubMed ID: 21910079
[TBL] [Abstract][Full Text] [Related]
16. Targeting sphingolipid metabolism in the treatment of obesity/type 2 diabetes.
Bellini L; Campana M; Mahfouz R; Carlier A; Véret J; Magnan C; Hajduch E; Le Stunff H
Expert Opin Ther Targets; 2015; 19(8):1037-50. PubMed ID: 25814122
[TBL] [Abstract][Full Text] [Related]
17. Sphingolipids and phospholipids in insulin resistance and related metabolic disorders.
Meikle PJ; Summers SA
Nat Rev Endocrinol; 2017 Feb; 13(2):79-91. PubMed ID: 27767036
[TBL] [Abstract][Full Text] [Related]
18. Ceramides in Metabolism: Key Lipotoxic Players.
Chaurasia B; Summers SA
Annu Rev Physiol; 2021 Feb; 83():303-330. PubMed ID: 33158378
[TBL] [Abstract][Full Text] [Related]
19. Ceramides in insulin resistance and lipotoxicity.
Summers SA
Prog Lipid Res; 2006 Jan; 45(1):42-72. PubMed ID: 16445986
[TBL] [Abstract][Full Text] [Related]
20. Sphingolipids in obesity, type 2 diabetes, and metabolic disease.
Russo SB; Ross JS; Cowart LA
Handb Exp Pharmacol; 2013; (216):373-401. PubMed ID: 23563667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
